Some comments on treating w/ the @Regeneron monoclonal antibody infusion. 1. @statnews piece by @matthewherperstatnews.com/2020/09/29/reg…
and company press release with more extensive data
The viral load clearing effects were related to being antibody negative
2. The dose given (8 g) was the highest tested. There were also non-human primate studies.
Here is the main paper @ScienceMagazine rationale for the "cocktail" as compared to a single monoclonal for the other antibody programs. science.sciencemag.org/content/369/65…
3. Here are the prophylaxis and treatment data preprint in macaques and hamsters biorxiv.org/content/10.110…
5. That's the summary of the data set for this experimental therapy. So far safety has not been a stumbling block. But what isn't known is the indication for using it today as "precautionary." Still many unknowns about the mAbs, too.
6. BTW both companies (@LillyPad and @Regeneron) with release of their small Phase 2 trials have asserted they have enough data to apply for an FDA emergency use authorization. I disagree, but that's a different matter.
7. @Regeneron's note today on their compassionate use program investor.regeneron.com/static-files/f…
That's not really a clinical trial. It's an open use of drug w/o controls, provides some safety data. Would be interesting to learn how many patients received the mAb to date in this program.
8. Now Len Schleifer, CEO of @Regeneron on @CNN talking w/ @wolfblitzer. Justifying it as a "fair fight" for boosting immune response. Also doesn't comment on ? of possible infusion of the mAb to @FLOTUS
• • •
Missing some Tweet in this thread? You can try to
force a refresh
As I wrote in SUPER AGERS, the immune system is the key to modulating our aging process and the opportunity to extend healthspan. Today @NatureAging 7 new articles, summarized here, that reinforce its central role nature.com/articles/s4358…
The new special issue @ScienceMagazine features Immunity with 4 outstanding review papers, 5★
Our immune system over the lifespan, sex differences, influence on physiology, and host antiviral defenses science.org/toc/science/cu…
We've learned a lot more about the principal drivers of age-related diseases in the past few weeks. And that leads to a unified model to pull it all together. (open-access)
I review 4 new reports, summarized here: 1. The proteins from senescent cells predict age-related clinical outcomes 2. A new epigenetic age clock connects the dots between aging, the immune system, inflammation and lifestyle factors 3. People with a fast pace of aging had an increased risk of cognitive impairment, age-related diseases, disability, and mortality 4. The Importance of “Immune Resilience” for Healthspan
And present a unified I/I model for what we now know
Most people haven’t heard of this test, which is available in the US. It accurately predicts Alzheimer’s (not just if there’s a risk, but when). It is favorably affected by exercise and likely many other lifestyle factors.
Here’s (almost) everything we know about it. In Ground Truths (link in my profile d/t X-suppression)
A major @Nature paper this week found a significant decline in dementia after an outdated Shingles vaccine.
I've reviewed the study and many other relevant ones in a new Ground Truths (link in profile)
A Table from the post
The effect in the 2 natural experiments differed substantially by sex with the benefit predominant in women
The vaccine against Shingles helps protect against dementia, results of a natural experiment, adding to prior evidence
"implications are profound"
New @Nature nature.com/articles/s4158… nature.com/articles/d4158…